(Q59443140)

1 July 2019

title

Mechanisms of NAFLD development and therapeutic strategies. (English)

1 reference

1 July 2019

author

Scott L. Friedman

1

1 reference

1 July 2019

author name string

Mary Rinella

3

1 reference

1 July 2019

Brent A Neuschwander-Tetri

2

1 reference

1 July 2019

Arun J Sanyal

4

1 reference

1 July 2019

language of work or name

English

0 references

publication date

2 July 2018

1 reference

1 July 2019

published in

Nature Medicine

1 reference

1 July 2019

volume

24

1 reference

1 July 2019

issue

7

1 reference

1 July 2019

page(s)

908-922

1 reference

1 July 2019

https://scigraph.springernature.com/pub.10.1038/s41591-018-0104-9

exact match

0 references

cites work

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The global NAFLD epidemic

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Management of NAFLD: a stage-based approach

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Complex genetics of pulmonary diseases: lessons from genome-wide association studies and next-generation sequencing

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A comprehensive definition for metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Genetic predisposition in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Genetic modifiers of non-alcoholic fatty liver disease progression

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Genetics and epigenetics of NAFLD and NASH: Clinical impact

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The roles of c-Jun NH2-terminal kinases (JNKs) in obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Incomplete absorption of pure fructose in healthy subjects and the facilitating effect of glucose

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Ability of the normal human small intestine to absorb fructose: evaluation by breath testing

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fatty acid metabolism: target for metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Clinical relevance of the bile acid receptor TGR5 in metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Brown and Beige Fat: Physiological Roles beyond Heat Generation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

NASH: a mitochondrial disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The Role of Cholesterol in the Pathogenesis of NASH.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The role of ER stress in lipid metabolism and lipotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Inflammasome activation and function in liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Adipokines in liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Obesity-induced hepatic steatosis is mediated by endoplasmic reticulum stress in the subfornical organ of the brain

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Inflammasome is a central player in the induction of obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Insulin resistance: a metabolic pathway to chronic liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A stress signaling pathway in adipose tissue regulates hepatic insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The role of cytokines in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Non-alcoholic fatty liver and the gut microbiota

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Commensal bacteria make GPCR ligands that mimic human signalling molecules

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Interactions between bile salts, gut microbiota, and hepatic innate immunity.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Lipotoxicity and the gut-liver axis in NASH pathogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Intestinal microbiota and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The role of the gut microbiota in NAFLD.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Mechanisms of hepatic stellate cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Mutant PNPLA3 I148M protein as pharmacological target for liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Preclinical models of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A Simple Diet- and Chemical-Induced Murine NASH Model with Rapid Progression of Steatohepatitis, Fibrosis and Liver Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Liver-directed microRNA-7a depletion induces nonalcoholic fatty liver disease by stabilizing YY1-mediated lipogenic pathways in zebrafish.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Role of fat body lipogenesis in protection against the effects of caloric overload in Drosophila

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Three Pillars for the Neural Control of Appetite

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Fibroblast Growth Factor 21-Metabolic Role in Mice and Men.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Thyroid Hormone Receptor β Agonist Induces β-Catenin-Dependent Hepatocyte Proliferation in Mice: Implications in Hepatic Regeneration

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

ERRγ Preserves Brown Fat Innate Thermogenic Activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Development of novel combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Pharmacotherapy for NASH: Current and emerging.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Drug development: Sprint finish.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Positional cloning of the mouse obese gene and its human homologue

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Diabetes, a New Mutation in the Mouse

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Liver fibrosis in overweight patients

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0104-9

7 January 2021

Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29967350

12 December 2020

inferred from PubMed ID database lookup

A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29967350

12 December 2020

inferred from PubMed ID database lookup

Fibroblast Growth Factor Signaling in Metabolic Regulation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29967350

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/S41591-018-0104-9

1 reference

1 July 2019

PMC publication ID

6553468

1 reference

1 July 2019

PubMed publication ID

29967350

1 reference

1 July 2019